{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:44:03Z","timestamp":1777495443155,"version":"3.51.4"},"reference-count":139,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine (Lond.)"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.2217\/nnm-2018-0348","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T15:41:24Z","timestamp":1559749284000},"page":"1471-1491","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":47,"title":["Nanomedicine as a Future Therapeutic Approach for Hepatitis C Virus"],"prefix":"10.1080","volume":"14","author":[{"given":"Noura H","family":"Abd Ellah","sequence":"first","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, Medical Sciences Building, University of Cincinnati, Cincinnati, OH45267, USA"},{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut71526, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham M","family":"Tawfeek","sequence":"additional","affiliation":[{"name":"Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Assiut71526, Egypt"},{"name":"Department of Pharmaceutics & Pharmaceutical Technology, Faculty of Pharmacy, Mutah University, Karak, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3343-8677","authenticated-orcid":false,"given":"James","family":"John","sequence":"additional","affiliation":[{"name":"Central Research Facilities, Sri Ramachandra institute of higher education & research, Sri Ramachandra University, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8541-7304","authenticated-orcid":false,"given":"Helal F","family":"Hetta","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology & Immunology, Faculty of Medicine, Assiut University, Assiut71526, Egypt"},{"name":"Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH45267-0595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"WHO . Hepatitis(2018). www.who.int\/hepatitis\/news-events\/hep-c-scale-up\/en\/"},{"key":"e_1_3_2_3_1","unstructured":"Centers for disease control and prevention. . Hepatitis C FAQs for health professionals. Division of viral hepatitis website (2018). www.cdc.gov\/hepatitis\/HCV\/HCVfaq.htm"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1006613"},{"issue":"1","key":"e_1_3_2_5_1","first-page":"13","article-title":"Preparation and characterization of PLGA nanoparticles containing recombinant core\u2013NS3 fusion protein of hepatitis C virus as a nano-vaccine candidate","volume":"4","author":"Hekmat S","year":"2017","unstructured":"Hekmat S , AslaniM , ShafieeArdestani Met al. Preparation and characterization of PLGA nanoparticles containing recombinant core\u2013NS3 fusion protein of hepatitis C virus as a nano-vaccine candidate. Vaccine Res.4(1), 13\u201318 (2017).","journal-title":"Vaccine Res."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2010.02.003"},{"issue":"6","key":"e_1_3_2_7_1","first-page":"757","article-title":"Investigation of HCV multi-epitope gene vaccine loaded by CTS\u2013Fe3O4","volume":"42","author":"Yang Y","year":"2011","unstructured":"Yang Y , KuangY , YuanDet al. Investigation of HCV multi-epitope gene vaccine loaded by CTS\u2013Fe3O4. Sichuan Da Xue Xue Bao Yi Xue Ban42(6), 757\u2013761, 788 (2011).","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.07.001"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-0521"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00604-012-0842-1"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201600416"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201604139"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24219"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/nn302538y"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2015.1108375"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.01.026"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.08.014"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/2331205X.2017.1418133"},{"key":"e_1_3_2_19_1","article-title":"Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C","volume":"6","author":"Duan L","year":"2016","unstructured":"Duan L , YanY , LiuJet al. Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C. Sci. Rep.6, 24867 (2016).","journal-title":"Sci. Rep."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197504102921502"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.391"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.02.022"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-017-0753-1"},{"key":"e_1_3_2_24_1","first-page":"578","article-title":"Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs","volume":"15","author":"Saleem A","year":"2016","unstructured":"Saleem A , AkhtarMF , MushtaqMFet al. Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs. EXCLI. J.15, 578 (2016).","journal-title":"EXCLI. J."},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290122"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.8.3.333"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.81364-0"},{"issue":"5","key":"e_1_3_2_28_1","first-page":"31","article-title":"Current and future prophylactic vaccines for hepatitis C virus","author":"Dunlop J","year":"2015","unstructured":"Dunlop J , OwsiankaA , CowtonV , PatelA. Current and future prophylactic vaccines for hepatitis C virus. Vaccine: Devel. Ther.2015(5), 31\u201344 (2015).","journal-title":"Vaccine: Devel. Ther."},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.33909"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i2.862"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2013.00212"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300620"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9946"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-016-3015-4"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39133"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385032-4.00002-1"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2015.0093"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607026104"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20060171"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.12.5550-5558.2001"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.033"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20856"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.5411\/wji.v4.i2.52"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000272"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12936"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04079"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1086\/529379"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-181368"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2018.07.004"},{"key":"e_1_3_2_50_1","first-page":"1182A","article-title":"Significant correlations between the frequency of colonic mucosal Treg cells with the viral load and liver inflammation in HCV-infected patients","volume":"58","author":"Hetta HF","year":"2013","unstructured":"Hetta HF , MekkyMA , KhalilNKet al. Significant correlations between the frequency of colonic mucosal Treg cells with the viral load and liver inflammation in HCV-infected patients. Hepatol.58, 1182A (2013).","journal-title":"Hepatol."},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(14)60913-6"},{"issue":"6","key":"e_1_3_2_52_1","first-page":"983","article-title":"Evaluation of circulating CD4+CD25+ and liver-infiltrating Foxp3+ cells in HCV-associated liver disease","volume":"29","author":"Amoroso A","year":"2012","unstructured":"Amoroso A , D\u2019amicoF , ConsoloMet al. Evaluation of circulating CD4+CD25+ and liver-infiltrating Foxp3+ cells in HCV-associated liver disease. Int. J. Mol. Med.29(6), 983\u2013988 (2012).","journal-title":"Int. J. Mol. Med."},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890150102"},{"issue":"9","key":"e_1_3_2_54_1","first-page":"803","article-title":"Role of interleukin-6, gamma interferon and adenosinedeaminase markers in management of pleural effusion patients","volume":"62","author":"Marie MA","year":"2013","unstructured":"Marie MA , JohnJ , KrishnappaLG , GopalkrishnanS , BinduraniSR. Role of interleukin-6, gamma interferon and adenosinedeaminase markers in management of pleural effusion patients.West Indian Med. J.62 (9), 803\u2013807 (2013).","journal-title":"West Indian Med. J."},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26371"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21747"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.2213"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1267535"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.184"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01617.x"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.022"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22547"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24692"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.018"},{"issue":"2","key":"e_1_3_2_66_1","first-page":"1016","article-title":"DAA (direct-acting antivirals) and HATs (host-targeting antivirals) in 2014","volume":"2","author":"Tajima A","year":"2014","unstructured":"Tajima A . DAA (direct-acting antivirals) and HATs (host-targeting antivirals) in 2014. JSM Gastroenterol. Hepatol.2(2), 1016 (2014).","journal-title":"JSM Gastroenterol. Hepatol."},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.81503-0"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82465-0"},{"issue":"1","key":"e_1_3_2_69_1","first-page":"129","article-title":"Treatment and vaccination for hepatitis C: present and future","volume":"20","author":"Jawaid A","year":"2008","unstructured":"Jawaid A , KhuwajaAK. Treatment and vaccination for hepatitis C: present and future. J. Ayub Med. Coll. Abbottabad20(1), 129\u2013133 (2008).","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2323"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.09.001"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1225416"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.4.1294"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3589"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.058"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.06.027"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21319"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.11.10.9271360"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.07.011"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1590\/1678-457X.6515"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200218"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312019"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2016.02.015"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0561-z"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1522080113"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005211107"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2008.07.007"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2018.04.052"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S2.1.19"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1207766109"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2011.12.015"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181723"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2016.08.018"},{"issue":"4","key":"e_1_3_2_94_1","first-page":"189","article-title":"From in silico immunogenicity verification to in vitro expression of recombinant core\u2013NS3 fusion protein of HCV","volume":"118","author":"Hekmat S","year":"2017","unstructured":"Hekmat S , SiadatS , AghasadeghiMet al. From in silico immunogenicity verification to in vitro expression of recombinant core\u2013NS3 fusion protein of HCV. Bratisl. Lek. Listy118(4), 189\u2013195 (2017).","journal-title":"Bratisl. Lek. Listy"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7PY00385D"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(02)00002-0"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i23.7242"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.32"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002876"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7AY01086A"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2016.11.001"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2017.02.007"},{"issue":"12","key":"e_1_3_2_103_1","first-page":"2240","article-title":"Significance of the hepatitis C virus core antigen testing as an alternative marker for hepatitis diagnosis in Egyptian patients","volume":"19","author":"Soliman H","year":"2015","unstructured":"Soliman H , HozayenW , MahmoudA , Abo-SeifM , FayedN. Significance of the hepatitis C virus core antigen testing as an alternative marker for hepatitis diagnosis in Egyptian patients. Eur. Rev. Med. Pharmacol. Sci.19(12), 2240\u20132245 (2015).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja0706504"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1586\/erm.09.33"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00064-8"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i42.15476"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6346(03)00113-X"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1387-1811(97)00024-3"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph14010011"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201301131"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.00236.x"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003030200"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1609"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S2263"},{"key":"e_1_3_2_116_1","unstructured":"Abo-Zeid YM UrbanowiczRA TarrAW IrvingWL ThomsonBJ GarnettMC. Nanoparticles as a promising delivery system to improve hepatitis C treatment (2014).www.semanticscholar.org\/paper\/Nanoparticles-as-a-Promising-Delivery-System-to-C-Abo-zeid-Urbanowicz\/653ba60c026716b8f040cefa70f86ceedfb037b4"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2013.1608"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712380105"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1021\/cb900149b"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408617200"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1261\/rna.1901810"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.50"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07756"},{"issue":"1","key":"e_1_3_2_124_1","first-page":"1","article-title":"The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target","volume":"9","author":"Frick DN","year":"2007","unstructured":"Frick DN . The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr. Issues Mol. Biol.9(1), 1\u201320 (2007).","journal-title":"Curr. Issues Mol. Biol."},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00179-5"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016464"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2012.5173"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26260"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.012"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2015.06.010"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/67.5.960S"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina54050080"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6020051"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-017-0370-4"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2016.1213238"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01317-07"},{"issue":"1","key":"e_1_3_2_138_1","article-title":"HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice","volume":"8","author":"Lee SH","year":"2018","unstructured":"Lee SH , MoonJS , PakBYet al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci. Rep.8(1), 12469 (2018).","journal-title":"Sci. Rep."},{"issue":"12","key":"e_1_3_2_139_1","first-page":"742","article-title":"Progress in nanomedicine: approved and investigational nanodrugs","volume":"42","author":"Ventola CL","year":"2017","unstructured":"Ventola CL . Progress in nanomedicine: approved and investigational nanodrugs. Pharm. Ther.42(12), 742\u2013755 (2017).","journal-title":"Pharm. Ther."},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)00177-X"}],"container-title":["Nanomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nnm-2018-0348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:48:54Z","timestamp":1716493734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nnm-2018-0348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":139,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.2217\/nnm-2018-0348"],"URL":"https:\/\/doi.org\/10.2217\/nnm-2018-0348","relation":{},"ISSN":["1743-5889","1748-6963"],"issn-type":[{"value":"1743-5889","type":"print"},{"value":"1748-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=innm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=innm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}